A Facebook post reports the TRIUMPH-2 result for Lilly's triple agonist in people with type 2 diabetes. Few details beyond the headline number are given.
Recap by typeshit. Post by Facebook on Facebook.
Dr Alo, a cardiologist, says he is following the cardiovascular data on these drugs closely and that it is shifting how heart disease is treated.
50:28
DOWNSIZED looks at why appetite and food noise can creep back late in the weekly cycle, and what that may say about whether a GLP-1 is still working.
Avi Roy points to trial data on drugs like Ozempic, including a 16-week study of 73 people where milkshake ratings barely changed despite reduced appetite.
Research presented at the anesthesiology meeting linked GLP-1 use with lower odds of heart attack and other heart problems. It shows an association, not proof of cause.
Lawmaker data counted 5,973 gallstone and 1,264 pancreatitis cases after prescriptions. Endocrinologists say rapid weight loss and glucose shifts may explain some.
Nacionale reports on research looking at whether GLP-1 drugs connect to involvement with the justice system and to keeping steady work.
Loading…